Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
Citations
671 citations
539 citations
345 citations
297 citations
294 citations
Cites background from "Analysis of Circulating Cell-Free D..."
...…ovarian, pancreatic, and prostate carcinoma (Sakai et al. 2008; Norquist et al. 2011; Barber et al. 2013; Patch et al. 2015; Christie et al. 2017; Goodall et al. 2017; Kondrashova et al. 2017; Lheureux et al. 2017a; Pishvaian et al. 2017; Quigley et al. 2017; Weigelt et al. 2017; Lin et al. 2019)....
[...]
...Since then, many examples of secondary mutations in BRCA1/2, as well as RAD51C, RAD51D, and PALB2, that genetically revert the mutation and restore functional full-length protein have been reported in breast, ovarian, pancreatic, and prostate carcinoma (Sakai et al. 2008; Norquist et al. 2011; Barber et al. 2013; Patch et al. 2015; Christie et al. 2017; Goodall et al. 2017; Kondrashova et al. 2017; Lheureux et al. 2017a; Pishvaian et al. 2017; Quigley et al. 2017; Weigelt et al. 2017; Lin et al. 2019)....
[...]
References
272,030 citations
45,957 citations
43,862 citations
20,557 citations
18,858 citations